CARM vs. EGRX, KRON, AEON, CALC, ANEB, IMMX, ELDN, MURA, TLSA, and KZR
Should you be buying Carisma Therapeutics stock or one of its competitors? The main competitors of Carisma Therapeutics include Eagle Pharmaceuticals (EGRX), Kronos Bio (KRON), AEON Biopharma (AEON), CalciMedica (CALC), Anebulo Pharmaceuticals (ANEB), Immix Biopharma (IMMX), Eledon Pharmaceuticals (ELDN), Mural Oncology (MURA), Tiziana Life Sciences (TLSA), and Kezar Life Sciences (KZR). These companies are all part of the "pharmaceutical preparations" industry.
Eagle Pharmaceuticals (NASDAQ:EGRX) and Carisma Therapeutics (NASDAQ:CARM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, community ranking, institutional ownership, earnings, media sentiment and analyst recommendations.
Eagle Pharmaceuticals currently has a consensus target price of $17.00, suggesting a potential upside of 257.89%. Carisma Therapeutics has a consensus target price of $8.60, suggesting a potential upside of 527.74%. Given Eagle Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Carisma Therapeutics is more favorable than Eagle Pharmaceuticals.
Eagle Pharmaceuticals has higher revenue and earnings than Carisma Therapeutics. Carisma Therapeutics is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Carisma Therapeutics had 8 more articles in the media than Eagle Pharmaceuticals. MarketBeat recorded 10 mentions for Carisma Therapeutics and 2 mentions for Eagle Pharmaceuticals. Carisma Therapeutics' average media sentiment score of 0.94 beat Eagle Pharmaceuticals' score of -0.01 indicating that Eagle Pharmaceuticals is being referred to more favorably in the media.
85.4% of Eagle Pharmaceuticals shares are owned by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are owned by institutional investors. 28.9% of Eagle Pharmaceuticals shares are owned by company insiders. Comparatively, 17.0% of Carisma Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Eagle Pharmaceuticals received 401 more outperform votes than Carisma Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Carisma Therapeutics an outperform vote while only 70.67% of users gave Eagle Pharmaceuticals an outperform vote.
Eagle Pharmaceuticals has a beta of 0.46, meaning that its share price is 54% less volatile than the S&P 500. Comparatively, Carisma Therapeutics has a beta of 1, meaning that its share price has a similar volatility profile to the S&P 500.
Eagle Pharmaceuticals has a net margin of 0.00% compared to Eagle Pharmaceuticals' net margin of -538.81%. Carisma Therapeutics' return on equity of 0.00% beat Eagle Pharmaceuticals' return on equity.
Summary
Eagle Pharmaceuticals beats Carisma Therapeutics on 11 of the 18 factors compared between the two stocks.
Get Carisma Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CARM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CARM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Carisma Therapeutics Competitors List
Related Companies and Tools
